Existing safety databases and pharmacological reviews do not flag a contraindication to combined use
Semaglutide was added in 2024, and markers of tirzepatide were added from 1 January 2026, both monitored in and out of competition
This trial not only supports the medications role in weight loss but also highlights its potential in reducing cardiovascular risk, adding to its overall therapeutic value
Restriction to milligram unit records: To ensure consistency, records were further restricted to those reporting cumulative doses in milligrams, yielding a final dataset of records
Atti XVII Riunione AISG, Rapallo 2223 Marzo 2002, Tipografia IDEAL Torino 2004 Revoltella RP, Dal Canto B, Caracciolo L, et al
Attaining a brighter complexion is a desire shared by many, and glutathione offers promising benefits in this regard